Efficacy of Platelet-Rich Plasma Injection in Dry Eye Syndrome

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · Feb 14, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at the use of Platelet-Rich Plasma (PRP) injections to help improve tear production in people suffering from severe dry eye syndrome. Dry eye syndrome can cause discomfort and vision problems, and this study aims to see if injecting PRP into the lacrimal gland (the gland that produces tears) can help restore proper tear secretion in those who have a specific type of dry eye caused by a lack of tears.

To be eligible for this trial, participants should be between the ages of 65 and 74 and must have been diagnosed with severe dry keratoconjunctivitis, a serious form of dry eye. They will also need to have normal platelet counts and clotting factors. However, individuals with certain conditions, like significant scarring in the eye or a complete blockage of the tear ducts, will not be able to participate. If you join the study, you can expect to receive the PRP injection and be monitored by medical professionals to see how well it helps your symptoms. This trial is currently recruiting participants, and it's a chance to explore a potential new treatment for dry eye syndrome.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Platelet counts, and clotting factors in the standarts
• • Presenting with severe dry keratoconjunctivitis diagnosed by an ophthalmologist
• Exclusion Criteria:
• • Patients with significant fibrosis of the conjunctival portion of the lacrimal gland
• • Patients with complete stenosis of both lacrimal meatus in the treated eye